Number of viral quasispecies in each of the 33 patients from whom paired T0-baseline and T1-1 month after baseline-blood and seminal samples were available
| Patient | T0 | T1 | Antiretroviral regimen | ||
| Blood | Seminal plasma | Blood | Seminal plasma | ||
| 1 | 3 | 6 | 1 | 2 | TDF+FTC+RPV |
| 2 | 5 | 7 | 0 | 0 | TDF+FTC+RPV |
| 3 | 4 | 6 | 1 | 1 | TDF+FTC+RPV |
| 4 | 1 | 3 | 1 | 1 | TDF+FTC+RPV |
| 5 | 2 | 4 | 1 | 2 | TDF+FTC+DRV/rtv |
| 6 | 4 | 7 | 2 | 4 | TDF+FTC+DRV/rtv |
| 7 | 7 | 10 | 3 | 6 | TDF+FTC+DRV/rtv |
| 8 | 3 | 4 | 1 | 1 | TDF+FTC+DRV/rtv |
| 9 | 4 | 5 | 1 | 1 | TDF+FTC+DRV/rtv |
| 10 | 2 | 3 | 0 | 0 | TDF+FTC+DRV/rtv |
| 11 | 5 | 8 | 0 | 0 | TDF+FTC+EVG/c |
| 12* | 2 | 4 | 0 | 0 | TAF+FTC+EVG/c |
| 13 | 2 | 3 | 0 | 0 | TAF+FTC+EVG/c |
| 14 | 3 | 6 | 0 | 0 | TAF+FTC+EVG/c |
| 15 | 2 | 3 | 1 | 2 | TAF+FTC+EVG/c |
| 16 | 1 | 2 | 0 | 0 | TAF+FTC+EVG/c |
| 17 | 3 | 6 | 1 | 2 | TAF+FTC+EVG/c |
| 18 | 2 | 7 | 0 | 0 | TAF+FTC+EVG/c |
| 19 | 8 | 11 | 0 | 6 | TAF+FTC+EVG/c |
| 20 | 4 | 2 | 0 | 1 | TAF+FTC+EVG/c |
| 21 | 3 | 5 | 0 | 0 | TAF+FTC+EVG/c |
| 22* | 7 | 11 | 3 | 5 | TAF+FTC+EVG/c |
| 23* | 3 | 6 | 0 | 5 | TAF+FTC+EVG/c |
| 24 | 2 | 4 | 1 | 6 | TAF+FTC+EVG/c |
| 25 | 5 | 7 | 0 | 3 | TAF+FTC+DRV/c |
| 26 | 6 | 11 | 0 | 0 | 3TC+ABC+DTG |
| 27 | 3 | 6 | 0 | 0 | 3TC+ABC+DTG |
| 28 | 3 | 5 | 0 | 0 | 3TC+ABC+DTG |
| 29 | 5 | 8 | 0 | 0 | 3TC+ABC+DTG |
| 30* | 6 | 9 | 0 | 0 | 3TC+ABC+DTG |
| 31 | 1 | 2 | 0 | 0 | 3TC+ABC+DTG |
| 32 | 4 | 8 | 0 | 0 | 3TC+ABC+DTG |
| 33 | 2 | 4 | 1 | 1 | 3TC+ABC+DTG |
*Patients with acute infection. 0: undetectable viral load, no quasispecies were detected.
ABC, abacavir; DRV/rtv, darunavir/ritonavir; DTG, dolutegravir; DTG, dolutegravir; EVG/c, elvitegravir/cobicistat; FTC, emtricitabine; RPV, rilpivirine; TAF, tenofovir alafenamide; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.